BRPI0411762A - derivados de difenilpiridina, seu preparo e sua aplicação em terapêutica - Google Patents

derivados de difenilpiridina, seu preparo e sua aplicação em terapêutica

Info

Publication number
BRPI0411762A
BRPI0411762A BRPI0411762-0A BRPI0411762A BRPI0411762A BR PI0411762 A BRPI0411762 A BR PI0411762A BR PI0411762 A BRPI0411762 A BR PI0411762A BR PI0411762 A BRPI0411762 A BR PI0411762A
Authority
BR
Brazil
Prior art keywords
preparation
application
substituted
diphenylpyridine
alkyl group
Prior art date
Application number
BRPI0411762-0A
Other languages
English (en)
Inventor
Francis Barth
Laurent Hortala
Murielle Rinaldi-Carmona
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of BRPI0411762A publication Critical patent/BRPI0411762A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

"DERIVADOS DE DIFENILPIRIDINA, SEU PREPARO E SUA APLICAçãO EM TERAPêUTICA". A presente invenção refere-se aos derivados de 5,6-difenilpiridina-3-carboxamida, de fórmula geral (I): na qual: R~ 1~ representa o hidrogênio ou UM (C~ 1~-C~ 4~) alquila; R~ 2~ representa: um radical heterocíclico mononitrogenado, saturado, de 5 a 7 átomos de, o átomo de nitrogênio sendo substituído por um grupo (C~ 1~C~ 4~)alcanoíla; um grupo NR~ 10~R~ 11~; um radical carbocíclico não-aromático em C~ 3~-C~ 10~ substituído mais de 3 vezes por um grupo (C~ 1~-C~ 4~) alquila; . um radical carbocíclico não-aromático em C~ 11~-C~ 12~, não-substituído ou substituído uma ou várias vezes por um grupo (C~ 1~-C~ 4~)alquila; . um radical heterocíclico monooxigenado, saturado de 5 a 7 átomos, substituído mais de 3 vezes por um grupo (C~ 1~-C~ 4~)alquila; - ou R~ 1~ e R~ 2~ juntamente com o átomo de nitrogênio ao qual são ligados constituem um radical piperidin-1-ila dissubstituído em 4-assim como seus sais, seus solvatos e seus hidratos. Processo de preparo e aplicação em terapêutica.
BRPI0411762-0A 2003-06-26 2004-06-24 derivados de difenilpiridina, seu preparo e sua aplicação em terapêutica BRPI0411762A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0307757A FR2856684B1 (fr) 2003-06-26 2003-06-26 Derives de diphenylpyridine, leur preparation et leur application en therapeutique
PCT/FR2004/001581 WO2005000817A2 (fr) 2003-06-26 2004-06-24 Derives de diphenylpyridine, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
BRPI0411762A true BRPI0411762A (pt) 2006-08-08

Family

ID=33515448

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411762-0A BRPI0411762A (pt) 2003-06-26 2004-06-24 derivados de difenilpiridina, seu preparo e sua aplicação em terapêutica

Country Status (16)

Country Link
US (1) US7345059B2 (pt)
EP (1) EP1641758B1 (pt)
JP (1) JP4669839B2 (pt)
KR (1) KR20060025191A (pt)
CN (1) CN1832945A (pt)
AR (1) AR044906A1 (pt)
AT (1) ATE412635T1 (pt)
AU (1) AU2004251914B9 (pt)
BR (1) BRPI0411762A (pt)
CA (1) CA2528619A1 (pt)
DE (1) DE602004017463D1 (pt)
FR (1) FR2856684B1 (pt)
IL (1) IL172733A0 (pt)
MX (1) MXPA05014222A (pt)
TW (1) TW200504019A (pt)
WO (1) WO2005000817A2 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1492784A4 (en) 2002-03-28 2006-03-29 Merck & Co Inc SUBSTITUTED 2,3-DIPHENYLPYRIDINES
EP1546115A4 (en) 2002-09-27 2010-08-04 Merck Sharp & Dohme SUBSTITUTED PYRIMIDINES
MX2007012213A (es) 2005-04-06 2007-12-10 Hoffmann La Roche Derivados de piridin-3-carboxamida como agonistas inversos de canabinoides.
GB0514739D0 (en) * 2005-07-19 2005-08-24 Astrazeneca Ab Therapeutic agents
WO2007039797A1 (en) * 2005-10-03 2007-04-12 Pfizer Products Inc. Use of cannabinoid receptor-1 antagonist for treating inflammation and arthritis
FR2899899A1 (fr) * 2006-04-14 2007-10-19 Sanofi Aventis Sa Derives d'aminomethyl pyridine, leur preparation et leur application en therapeutique
US7629346B2 (en) 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
FR2904827B1 (fr) 2006-08-11 2008-09-19 Sanofi Aventis Sa Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antiganistes des recepteurs a l'urotensine ii
US7781593B2 (en) 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
FR2927330B1 (fr) 2008-02-07 2010-02-19 Sanofi Aventis Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antagonistes des recepteurs a l'urotensine ii
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
CN102276517B (zh) * 2011-06-29 2012-11-28 孙光辉 二芳基吡啶类药物的合成方法
SG11201502527UA (en) * 2012-10-05 2015-04-29 Rigel Pharmaceuticals Inc Gdf-8 inhibitors
JP6710273B2 (ja) * 2016-05-09 2020-06-17 日本曹達株式会社 環状アミン化合物および有害生物防除剤
IL311645A (en) 2016-07-12 2024-05-01 Revolution Medicines Inc 2,5-dimethomers of 3-methylpyrazines and 2,5,6-dimethomers of 3-methylpyrazines as allosteric SHP2 inhibitors
CA3051054A1 (en) 2017-01-23 2018-07-26 Revolution Medicines, Inc. Pyridine compounds as allosteric shp2 inhibitors
MX2019008695A (es) 2017-01-23 2019-09-11 Revolution Medicines Inc Compuestos biciclicos como inhibidores alostericos de shp2.
JP7356414B2 (ja) 2017-09-07 2023-10-04 レヴォリューション・メディスンズ，インコーポレイテッド がんを治療するためのｓｈｐ２阻害剤組成物および方法
JP2020536881A (ja) 2017-10-12 2020-12-17 レヴォリューション・メディスンズ，インコーポレイテッド アロステリックｓｈｐ２阻害剤としてのピリジン、ピラジンおよびトリアジン化合物
CN111433205B (zh) 2017-12-15 2024-01-19 锐新医药公司 作为变构shp2抑制剂的多环化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2198737B1 (pt) * 1972-09-13 1975-11-28 Serdex
FR2248027B2 (pt) * 1973-10-18 1977-09-09 Serdex
FR2612189B1 (fr) * 1987-03-13 1989-06-23 Roussel Uclaf Nouveaux derives de la pyridine, leur procede de preparation et les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions les renfermant
GB9210436D0 (en) * 1992-05-15 1992-07-01 Neave Andrew J A light projector for use in conjunction with light guides
FR2741621B1 (fr) * 1995-11-23 1998-02-13 Sanofi Sa Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
FR2816938B1 (fr) * 2000-11-22 2003-01-03 Sanofi Synthelabo Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant
EP1492784A4 (en) * 2002-03-28 2006-03-29 Merck & Co Inc SUBSTITUTED 2,3-DIPHENYLPYRIDINES
FR2838438A1 (fr) * 2002-04-11 2003-10-17 Sanofi Synthelabo Derives de diphenylpyridine,leur preparation, les compositions pharmaceutiques en contenant
FR2838439B1 (fr) * 2002-04-11 2005-05-20 Sanofi Synthelabo Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant

Also Published As

Publication number Publication date
CA2528619A1 (fr) 2005-01-06
JP2007514638A (ja) 2007-06-07
EP1641758A2 (fr) 2006-04-05
TW200504019A (en) 2005-02-01
US7345059B2 (en) 2008-03-18
AU2004251914B9 (en) 2010-02-25
AR044906A1 (es) 2005-10-05
JP4669839B2 (ja) 2011-04-13
WO2005000817A3 (fr) 2005-03-17
KR20060025191A (ko) 2006-03-20
MXPA05014222A (es) 2006-03-13
CN1832945A (zh) 2006-09-13
FR2856684A1 (fr) 2004-12-31
WO2005000817A2 (fr) 2005-01-06
AU2004251914A1 (en) 2005-01-06
EP1641758B1 (fr) 2008-10-29
FR2856684B1 (fr) 2008-04-11
ATE412635T1 (de) 2008-11-15
AU2004251914B2 (en) 2010-01-07
IL172733A0 (en) 2006-04-10
DE602004017463D1 (de) 2008-12-11
US20060189664A1 (en) 2006-08-24

Similar Documents

Publication Publication Date Title
BRPI0411762A (pt) derivados de difenilpiridina, seu preparo e sua aplicação em terapêutica
BRPI0607577A2 (pt) antagonistas cgrp, processo para sua preparação bem como seu uso como medicamento
PE20020476A1 (es) Derivados de glucopiranosiloxibencilbenceno y composiciones farmaceuticas que comprenden los mismos
BRPI0511581A (pt) derivados de tetrahidroisoquinolilsulfonamidas, sua preparação e sua utilização em terapêutica
NO20074391L (no) CIS-2,4,5-triaryl-imidazoliner og deres anvendelse som anti-cancer medikamenter
NO20076680L (no) Utvalgte CGRP-antagonister, metoder for fremstilling av disse og deres anvendelse som medikamenter
BRPI0615248A2 (pt) derivado tendo atividade agonista de ppar
BRPI0515133A (pt) derivados de uréia como bloqueadores do canal de cálcio
NO20050649L (no) Nye tiofenylglykosidderivater, fremgangsmate for fremstilling derav, medikamenter omfattende disse forbindelser og anvendelse derav
BRPI0507054A (pt) bloqueadores do canal de cálcio tipo n
BRPI0606964A2 (pt) pirrolidinas e piperidinas derivadas do acetileno para uso como antagonistas de mglur5
BR112012007069A2 (pt) derivado de fenol
CO5690593A2 (es) Nuevos derivados de pirimidin 2-amina
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
TW200800962A (en) Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
BRPI0900983B8 (pt) composto de diometina, processo para a síntese do mesmo, composição farmacêutica e seu uso
BRPI0813809A2 (pt) derivados de 7-alquinil -1,8-naftiridonas, sua preparação e sua aplicação em terapêutica.
BR0017063A (pt) Piperidinas substituìdas, composições farmacêuticas contendo estes compostos e processos para prepará-las
BR0311828A (pt) Derivados de 1-piperazinilacilpiperidina substituìdos, seu prepraro e sua aplicação em terapêutica
BR0108605A (pt) Derivados de 8,8a-dihidro-indeno[1,2-d]tiazol, que na posição 8a são substituìdos; processos para a sua preparação e seu emprego como medicamentos, por exemplo, como anoréxicos
BRPI0406500A (pt) processo farmacêutico e compostos preparados pelo mesmo
PE20060103A1 (es) Nuevas 5-acilindolinonas con contenido en cicloalquilo y su preparacion como medicamento
BRPI0501769A (pt) Compostos de pirrolidina e tiazolidina, processo para sua preparação e composições farmacêuticas contendo os mesmos
MXPA05013631A (es) Derivado heterociclico de metilsulfona.
NO20055167L (no) Nye benzotiadiazinforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014.